Immatics Biotechnologies GmbH
Immatics is a biopharmaceutical company dedicated to developing innovative T cell receptor-based immunotherapies for cancer treatment. With a focus on precision targeting of cancer-specific antigens like PRAME, Immatics combines advanced technology platforms with deep biological understanding to discover and develop novel therapies. The company operates globally with sites in Tübingen, Munich, and Houston, and collaborates with industry leaders to bring effective cancer immunotherapies to patients. Immatics' mission is to unlock the power of T cells to improve outcomes for cancer patients through its proprietary pipeline of adoptive cell therapies and TCR bispecifics.
Industries
Nr. of Employees
medium (51-250)
Immatics Biotechnologies GmbH
Paul-Ehrlich-Str. 15 – 19, 72076 Tuebingen, Germany
Patents
Peptides displayed by HLA for use in immunotherapy against different types of cancers
US-12318407-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US-12295996-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
US-12297254-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US-12295995-B2
View Details
Peptides displayed by HLA for use in immunotherapy against different types of cancers
US-12318407-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US-12295996-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
US-12297254-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US-12295995-B2
View DetailsProducts
PRAME-targeted autologous TCR-engineered cell therapy (clinical-stage)
Clinical-stage autologous TCR-T therapy directed at PRAME-expressing solid tumors; designed for single-dose infusion following patient leukapheresis and autologous manufacturing.
PRAME-targeted TCR bispecific (off-the-shelf biologic, clinical-stage)
A bispecific TCR-based T cell engager designed as a half-life–extended off-the-shelf biologic intended for repeat dosing in outpatient and hospital settings to target PRAME-positive tumors.
MAGEA4/8-targeted TCR bispecific (clinical-stage)
Clinical-stage TCR bispecific molecule targeting MAGEA4/8 for treatment of multiple solid tumor indications; developed in collaboration with external partners for clinical evaluation.
ACTallo® allogeneic gamma delta T cell product platform (preclinical/early development)
An off-the-shelf platform using gamma delta T cells sourced from healthy donors and engineered with CARs or TCRs to enable multiple doses from a single donor and HLA-independent use.
PRAME-targeted autologous TCR-engineered cell therapy (clinical-stage)
Clinical-stage autologous TCR-T therapy directed at PRAME-expressing solid tumors; designed for single-dose infusion following patient leukapheresis and autologous manufacturing.
PRAME-targeted TCR bispecific (off-the-shelf biologic, clinical-stage)
A bispecific TCR-based T cell engager designed as a half-life–extended off-the-shelf biologic intended for repeat dosing in outpatient and hospital settings to target PRAME-positive tumors.
MAGEA4/8-targeted TCR bispecific (clinical-stage)
Clinical-stage TCR bispecific molecule targeting MAGEA4/8 for treatment of multiple solid tumor indications; developed in collaboration with external partners for clinical evaluation.
ACTallo® allogeneic gamma delta T cell product platform (preclinical/early development)
An off-the-shelf platform using gamma delta T cells sourced from healthy donors and engineered with CARs or TCRs to enable multiple doses from a single donor and HLA-independent use.
Services
Clinical- and registration-directed GMP manufacturing and in-house QC testing for autologous and planned allogeneic cell therapy products; modular facility designed for scale-up.
Sponsorship and global execution of early- and late-stage oncology trials for TCR-T and bispecific molecules, including site selection and trial management across academic centers.
Research collaborations and licensing agreements with external biopharma partners to co-develop therapeutic modalities and combine platform capabilities.
Assessment and case-by-case review of physician-submitted requests for access to investigational therapies under regulatory expanded access pathways.
Clinical- and registration-directed GMP manufacturing and in-house QC testing for autologous and planned allogeneic cell therapy products; modular facility designed for scale-up.
Sponsorship and global execution of early- and late-stage oncology trials for TCR-T and bispecific molecules, including site selection and trial management across academic centers.
Research collaborations and licensing agreements with external biopharma partners to co-develop therapeutic modalities and combine platform capabilities.
Assessment and case-by-case review of physician-submitted requests for access to investigational therapies under regulatory expanded access pathways.
Expertise Areas
- Target discovery and validation for immunotherapy
- TCR discovery and engineering
- Autologous and allogeneic cell therapy development
- TCR bispecific (T cell engager) development
Key Technologies
- T cell receptor engineering
- Lentiviral transduction for T cell modification
- Gamma delta T cell allogeneic platform
- TCR-based bispecific T cell engagers
News & Updates
Data showing strong anti-tumor activity and durability in metastatic melanoma patients.
Financial results and updates on company progress.
Details about upcoming presentations at the 2025 ASCO Annual Meeting.
Data showing strong anti-tumor activity and durability in metastatic melanoma patients.
Financial results and updates on company progress.
Details about upcoming presentations at the 2025 ASCO Annual Meeting.